En Español | Plain Text Version | Skip Navigation

You are here:  Home > Funding & Research > Program Areas > Neurodegeneration

Genetics of Vascular Cognitive Impairment Workshop Agenda

Skip secondary menu

2004 Event Series Calendar

Genetics of Vascular Cognitive Impairment Workshop Participant List

Genetics of Vascular Cognitive Impairment Workshop
Bethesda Marriott
May 20-21, 2004

Agenda

Co-Chairs: Gabrielle G. Leblanc, Ph.D., and Vladimir Hachinski, M.D.

NINDS Organizing Committee: Gabrielle Leblanc, Ph.D., Katrina Gwinn-Hardy, M.D., Tom Jacobs, Ph.D., Diane Murphy, Ph.D., Emmeline Edwards, Ph.D.

Cosponsored by the Alzheimer's Association

The purpose of this workshop is to explore the feasibility of studies to identify genetic factors that render individuals more or less susceptible to cognitive impairment secondary to cerebrovascular disease. In particular, we will explore the ideas of developing a consortium of research teams to conduct genetic and/or epidemiological studies in vascular cognitive impairment and establishing a data coordinating center for such a consortium. This center could operate in partnership with NINDS's DNA repository to serve as a shared resource for the research community. Further specific goals of the workshop will be to develop recommendations concerning inclusion criteria for genetic studies and appropriate clinical measures of cognitive function. We will also consider potential cohorts for inclusion and include some brief discussion of genotyping platforms.

Thursday, May 20, 2004
5:30 p.m. Registration
6:30 p.m. Dinner Session
6:30 p.m. Workshop Rationale and Goals, Gabrielle Leblanc
7:00 p.m. "VCI and Genetics: The Challenge and the Opportunity," Vladimir Hachinski
7:30 p.m. Keynote Talk: "Genetic Approaches in Vascular Disease: Design and Execution," Donald Bowden
9:00 p.m. Adjourn for the Day


Friday, May 21, 2004
8:00 a.m. Continental Breakfast
8:30 a.m. "Proposed Consortium To Study Genetics of VCI," James Meschia
8:50 a.m. Discussion: Genetic Studies of VCI: Feasibility and Design
(Lead discussants: James Meschia, Eric Boerwinkle, Tatiana Foroud, and Donald Bowden)
  • Current evidence for heritability of susceptibility/resilience to cognitive impairment following ischemic insult
  • Possible cohorts/disease entities for study: focal ischemia, small vessel disease, TIA, hypertension, CABG, CADASIL, cerebral amyloid angiopathy
  • Study design, e.g., comparison of ischemic stroke patients with and without subsequent cognitive decline and patients with MRI pathology (or hypertension, CABG, CADASIL, etc.). that do better or worse in cognitive measures over time
  • Sample sizes needed
  • Inclusion of pre-existing patient cohorts, data collections
10:30 a.m. Discussion: Defining the Cerebrovascular Disease Phenotype
(Lead discussants: Stephen Salloway, Helena Chui, and Lenore Launer)
  • Definition of minimal diagnostic criteria for disease entity(ies) (for either genetic studies or a more general VCI data coordinating center)
  • Virtues of lumping versus splitting cohorts based on specific disease features
  • Potential use of CADASIL as a model disease phenotype
  • Inclusion of MRI, histopathological data
  • Use of currently existing brain banks
>
12:15 p.m. Lunch (on your own)
1:30 p.m. "Genetics of VCI: Exploring the Phenotypes," Charles DeCarli
1:50 p.m. Discussion: Defining the Cognitive Phenotype
(Lead discussants: Charles DeCarli, Donald Stuss, Claudia Kawas, and Jordan Grafman)
  • Pros and cons of currently available tests of cognitive function
  • Which tests best distinguish VCI from AD?
3:15 p.m. Discussion: Wrap-Up/Additional Ideas and Complementary Studies
(Discussion leaders: Katrina Gwinn-Hardy and Martin Dichgans)
  • Final thoughts on genetics issues
  • Animal models
  • Other research priorities for inclusion in "Genetics and Pathobiology of Vascular Cognitive Impairment" program announcement
  • Data sharing
4:00 p.m. Summary of Recommendations: Vladimir Hachinski/NIH Staff
4:30 p.m. Adjournment

Last updated February 09, 2005